Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.54 |
| ▸ | PRCP | P42785 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16499089 | 1.00 | HCRTR1 (0.54) | HCRTR1HCRTR2PRCP | |
| SCHEMBL16499547 | 0.91 | HCRTR1 (0.51) | HCRTR1HCRTR2PRCP | |
| SCHEMBL1293347 | 0.91 | HCRTR1 (0.64) | HCRTR1HCRTR2 | |
| SCHEMBL1293678 | 0.90 | HCRTR1 (0.51) | HCRTR1HCRTR2PRCP | |
| SCHEMBL16927259 | 0.88 | HCRTR1 (0.51) | HCRTR1HCRTR2PRCP | |
| SCHEMBL16499504 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL6123433 | 0.86 | HCRTR1 (0.47) | HCRTR1HCRTR2PRCP | |
| SCHEMBL629480 | 0.85 | PRCP (0.46) | HCRTR1HCRTR2PRCP | |
| SCHEMBL16499174 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2PRCP | |
| SCHEMBL1982288 | 0.85 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-108349945-B | HCV inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | HCRTR1 3674/4885HCRTR2 3725/4885PRCP 1873/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | HCRTR1 3674/4885HCRTR2 3725/4885PRCP 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.